Mechanisms of action of endocrine treatment in breast cancer
- 1 November 1995
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 21 (1-3) , 158-193
- https://doi.org/10.1016/1040-8428(94)00172-3
Abstract
No abstract availableKeywords
This publication has 370 references indexed in Scilit:
- Down-regulation of transforming growth factor-α by tamoxifen in human breast cancerCancer, 1993
- In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancerCancer Immunology, Immunotherapy, 1993
- Estrogen and Insulin Modulation of Intracellular Insulin-like Growth Factor Binding Proteins in Human Breast Cancer Cells: Possible Involvement in Lysosomal Hydrolases OversecretionBiochemical and Biophysical Research Communications, 1993
- Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatmentBreast Cancer Research and Treatment, 1992
- Identification of insulin-like growth factor binding proteins in breast cancer cellsBreast Cancer Research and Treatment, 1991
- Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7Biochemical and Biophysical Research Communications, 1989
- An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue cultureBiochemical and Biophysical Research Communications, 1987
- Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogensBiochemical and Biophysical Research Communications, 1987
- The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic proteaseBiochemical and Biophysical Research Communications, 1986
- Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesteraseBiochemical and Biophysical Research Communications, 1984